How the two Canadian tirzepatide products differ by indication, population and status.
Tirzepatide is one ingredient sold in Canada under two product names with different indications. Mounjaro is for type 2 diabetes. Zepbound is for chronic weight management and for obstructive sleep apnea with obesity. Neither is listed on any public drug plan reviewed by this site for any indication.
Paraphrases below come from each product's Canadian monograph as linked from its DPD record. They are not dosing guidance and not an eligibility check.
The short version
Mounjaro (vials and KwikPen) is Marketed for type 2 diabetes in adults and, since a 2026 label change, in ages 10 to under 18 in specified combinations. No weight-management indication in Canada.
Zepbound (KwikPen, six strengths) is Marketed since February 2026 for adult chronic weight management and for moderate to severe obstructive sleep apnea with obesity. No pediatric indication.
The single-dose Mounjaro pens are Approved but not Marketed; the vials and the KwikPen are Marketed.
No public plan reviewed lists tirzepatide; British Columbia's formulary has no tirzepatide listing at all. See the coverage record.
At a glance
Tirzepatide products in Canada at a glance, from each product's DPD record and monograph
Adults: chronic weight management with BMI 30 or more, or 27 to under 30 with a weight-related condition; moderate to severe obstructive sleep apnea with obesity (BMI 30 or more). Alongside reduced calories and increased activity. R21-C461A-C07
Marketed
2026-02-12 (7.5 mg 2026-02-16)
A DPD status says whether a product is authorized and whether the company reports it as sold. It does not say whether a pharmacy has it, whether a plan pays for it, or whether it suits anyone. Coverage is on the coverage page.
Product records
Mounjaro and Mounjaro KwikPen (tirzepatide; Eli Lilly Canada Inc; brand)
Canadian record for Mounjaro and Mounjaro KwikPen
Canadian indication (paraphrase of the product monograph)
Type 2 diabetes glycemic control in adults and in ages 10 to under 18 with specified combinations. Not a weight-management indication. R21-C460A-C06
Population
Adults and ages 10 to under 18 (pediatric indication change recorded 2026-06)
Single-dose vials 2.5 to 15 mg per 0.5 mL (Marketed); KwikPen multidose pens 2.5 to 15 mg per 0.6 mL, four doses (Marketed); single-dose prefilled pens (Approved, not marketed)
Unknown. Not researched by design; regulatory status never populates stock.
Zepbound (tirzepatide; Eli Lilly Canada Inc; brand)
Canadian record for Zepbound
Canadian indication (paraphrase of the product monograph)
Adults: chronic weight management with BMI 30 or more, or 27 to under 30 with a weight-related condition; moderate to severe obstructive sleep apnea with obesity (BMI 30 or more). Alongside reduced calories and increased activity. R21-C461A-C07
Unknown. Not researched by design; regulatory status never populates stock.
Other authorized weight-management and related products
For completeness, the other products that come up in the same conversations: two liraglutide products, naltrexone with bupropion, orlistat and setmelanotide. Each has its own indication and its own status.
Saxenda (liraglutide; Novo Nordisk Canada Inc; brand)
Canadian record for Saxenda
Canadian indication (paraphrase of the product monograph)
Chronic weight management in adults with BMI 30 or more, or 27 or more with a comorbidity, after a prior intervention did not work; ages 12 to under 18 with body weight above 60 kg, adult-equivalent BMI 30 or more and inadequate response to diet and activity. R21-C462A-C08
Unknown. Not researched by design; regulatory status never populates stock.
Victoza (liraglutide; Novo Nordisk Canada Inc; brand)
Canadian record for Victoza
Canadian indication (paraphrase of the product monograph)
Type 2 diabetes glycemic control in adults in specified combinations, and reduction of cardiovascular death with established cardiovascular disease; ages 10 and up as an adjunct to metformin. Not a weight-management indication. R21-C426R21-C427R21-C451R21-C452
Drug Shortages Canada report 240246 (updated 2025-10-06) gives an anticipated discontinuation date of 2027-01-01, status To be discontinued, business reasons. Earlier version said 2026-03-30. No stop date is published here because the report is anticipated, not actual.
Unknown. Not researched by design; regulatory status never populates stock.
Contrave (naltrexone and bupropion; Bausch Health, Canada Inc; brand)
Canadian record for Contrave
Canadian indication (paraphrase of the product monograph)
Adult chronic weight management with reduced calories and activity: BMI 30 or more, or 27 or more with a weight-related condition. Pediatric use is not authorized. R21-C428R21-C429R21-C436A-C09
The monograph lists contraindication topics including uncontrolled hypertension, seizure disorder, other bupropion products, chronic opioid use, and pregnancy. Read the monograph; this page gives no eligibility assessment.
Canadian indication (paraphrase of the product monograph)
Obesity management including weight loss, maintenance and reduced regain with a mildly reduced-calorie diet; BMI 30 or more, or 27 or more with risk factors. No authorized use below age 12. A-C10
Canadian indication (paraphrase of the product monograph)
Weight management from age 6 for obesity due to Bardet-Biedl syndrome or genetically confirmed biallelic POMC, PCSK1 or LEPR deficiency. Other obesity is excluded. R21-C430R21-C431R21-C443A-C11
The only direct trial of tirzepatide against semaglutide at weight-management doses is SURMOUNT-5. Its page in the evidence library gives the numbers as published, who was in the trial, and what it cannot tell you. This site does not rank medicines.
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
Source records for every claim cited on this page
Claim
What the source says
Source
Source date
Accessed
Label
R21-C460
Type 2 diabetes glycemic control: adults and ages 10 to <18 with specified combinations. Pediatric indication change recorded 2026-06. Presentations: single-dose vial/pen 2.5 to 15 mg per 0.5 mL; KwikPen 2.5 to 15 mg per 0.6 mL delivered, four doses.
Adults: chronic weight management (BMI ≥30 or 27 to <30 plus comorbidity) and moderate/severe OSA with obesity (BMI ≥30), alongside reduced calories/activity. OSA indication change 2026-06; no pediatric indication. KwikPen strengths 2.5/5/7.5/10/12.5/15 mg per 0.6 mL.
Chronic weight management in adults BMI ≥30 or ≥27 with comorbidity and failed prior intervention; ages 12 to <18 with >60 kg, adult-equivalent BMI ≥30 and inadequate diet/activity response. 6 mg/mL solution, 3 mL multidose pen; delivered strengths 0.6/1.2/1.8/2.4/3 mg.
Adult type 2 diabetes glycemic control with diet/activity when metformin is unsuitable; with metformin after inadequate response; with metformin plus sulfonylurea or SGLT2 inhibitor after inadequate dual therapy; or with metformin plus basal insulin after inadequate Victoza/metformin therapy. Also adjunct to diet/activity and standard care to reduce CV death in type 2 diabetes with established CVD. Ages ≥10: adjunct to metformin, with/without basal insulin, after diet/activity plus maximal tolerated metformin are inadequate.
6 mg/mL subcutaneous solution; 3 mL multidose pens (18 mg), delivering 0.6/1.2/1.8 mg. No 2025/2026 indication addition is identified in this PM’s recent-change list.
Current report 240246 (updated 2025-10-06) gives anticipated discontinuation and remaining-supply date 2027-01-01; actual discontinuation blank; status To be discontinued; business reasons.
History comparison shows the 2024-10-15 version had 2026-03-30; the 2025-10-06 version changed both anticipated discontinuation and remaining-supply dates to 2027-01-01.
Obesity weight management from age 6 for Bardet-Biedl syndrome or genetically confirmed biallelic POMC/PCSK1/LEPR deficiency (pathogenic, likely pathogenic or uncertain variants). Other obesity is excluded.
